Stocks · News reference
RBC Capital Markets Adjusts Price Target for Design Therapeutics
RBC Capital Markets maintained its 'Outperform' rating on Design Therapeutics while lowering its price target from $20 to $19.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Design Therapeutics Reports Third Quarter 2026 Financial Results
Design Therapeutics announced its financial results for the third quarter of 2026, reporting a net loss of $20.3 million and providing updates on its clinical-stage GeneTAC pipeline.
Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26
Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.
Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures mostly lower, Nasdaq 100 down 0.3%. Marvell Technology shares fall 7.6% after beating estimates, other stocks also drop in pre-market.